A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2023-08-08
AEs
4
Serious
1
Dropout signal
–
Adverse events
severe
serious
assessed
Grade 4 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-09-15 (study day 25); relationship: not assessed; serious criteria: life-threatening
moderate
assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-06-09 (study day 293); relationship: N
mild
assessed
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2024-07-24 (study day 338); relationship: not assessed
moderate
assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-09-18 (study day 394); relationship: N
Data queries
No data queries.